Healthcare Scan

Scan

Healthcare Scan

Scan symbols 19
SYKISRGMDTDXCMABTPFEMRKLLYGILDAMGNBIIBJNJUNHCVSVEEVTMOVRTXMRNAZTS
Watchlists 1
@healthcare
raw scan snapshot — prices as of scan date, not live 40 rows · screens, not recommendations

Healthcare is broadly RISK-ON now — large-cap pharma anchors that were soft last week have ripped (JNJ +6.4% 30D near ATH, MRK +7.4% 7D near ATH, AMGN +5.9% 30D), managed care still leads (UNH +55.9% 3M at ATH, CVS +47.2% 3M at ATH), and even lab-tools (TMO +13% 30D) bounced. The bifurcation is now narrower: only focused medtech (ISRG, SYK, MDT) and animal health (ZTS) plus healthcare-SaaS (VEEV) are still in collapse. PFE at RSI 27 is the lone deep-oversold name. Entry-frame: the leaders are mostly near ATH (don't chase); the cleanest setups are the basing large-caps (GILD, AMGN) and the washed-out PFE.

Source: healthcare.json. Latest bar 2026-06-25.

Quick Snapshot

Signal Reading
Overall 🟡 Broadly risk-on but bifurcated — managed care (UNH/CVS at ATH) + large-cap pharma (JNJ/MRK near ATH) + GLP-1/mRNA (LLY/MRNA) lead; focused medtech (ISRG/SYK/MDT) + animal health (ZTS) + SaaS (VEEV) still collapsing
Leaders CVS (RSI 72, +47.2% 3M, at ATH, +30% vs SMA200), VRTX (RSI 69, +10.2% 30D), UNH (RSI 67, +55.9% 3M, at ATH), JNJ (RSI 65, near ATH), MRK (RSI 65, near ATH), ABT (RSI 62, +7.7% 30D)
Laggards PFE (RSI 27↓, -7.5% 30D, below all SMAs), ISRG (RSI 38↓, -14.5% 3M, collapse), ZTS (RSI 40, -33% 3M, -51.9% from ATH, collapse), GILD (RSI 42, -6.5% 30D), VEEV (RSI 44, collapse)
Key insight The insurer/pharma re-rate now has the large-caps too (JNJ +6.4% 30D, MRK +7.4% 7D near ATH); the ONLY structural losers left are focused devices (ISRG/SYK/MDT) + ZTS + VEEV. PFE (RSI 27) is the lone washed-out name worth a watch

Price Table

Stock Price RSI vs SMA20 7D% 30D% 3M% 52wkHi% Signal
PFE $23.91 26.9 ↓ -6.4% -4.22% -7.50% -11.84% -16.85% 🔍 Watch (oversold, GC, -5.3% vs SMA200)
ISRG $400.52 37.6 ↓ -2.8% -1.02% -8.27% -14.52% -33.68% ❌ Don't Buy (collapse, DC)
ZTS $77.82 39.8 ↓ -1.1% -0.51% -3.00% -32.98% -51.89% ❌ Don't Buy (collapse, DC)
GILD $124.29 42.2 ↓ -1.9% +1.63% -6.45% -8.60% -20.98% 🔍 Watch (pullback, GC, -2.9% vs SMA200)
VEEV $158.08 44.3 ↓ -4.9% +5.76% -0.29% -11.33% -49.09% ❌ Don't Buy (collapse, DC)
DXCM $69.26 45.8 ↓ -5.2% -4.87% -3.82% +4.80% -23.03% 🔍 Watch (pullback, +2.9% vs SMA200)
SYK $316.11 55.9 +3.3% +1.65% +0.99% -4.72% -21.92% 🔍 Watch (downtrend, DC, -9.2% vs SMA200)
MDT $81.29 56.0 +2.7% +2.00% +4.76% -6.52% -23.55% 🔍 Watch (downtrend, DC, -10.5% vs SMA200)
BIIB $204.40 60.1 +3.8% +2.53% +5.86% +6.98% -1.09% 🔒 Hold (uptrend, GC, near ATH)
AMGN $355.86 60.5 +3.5% +4.40% +5.93% +1.53% -9.05% 🔒 Hold (basing, GC)
LLY $1,127.69 60.6 +0.9% +1.55% +5.91% +25.93% -4.65% 🔒 Hold (uptrend, GC, +16.1% vs SMA200)
TMO $505.75 64.0 +5.7% +6.73% +12.96% +3.56% -21.47% 🔍 Watch (weak-up, DC, -3.6% vs SMA200)
MRK $123.73 64.6 +5.2% +7.41% +4.09% +4.78% -1.13% 🔒 Hold (strong-up, GC, near ATH, +18.2% vs SMA200)
TGT‡ — — — — — — — —
ABT $93.37 61.7 +4.8% +1.81% +7.73% -10.15% -32.11% 🔍 Watch (weak-up, DC, -16.5% vs SMA200)
JNJ $244.84 65.1 +5.0% +5.38% +6.37% +2.93% -2.73% 🔒 Hold (basing, GC, near ATH, +13.9% vs SMA200)
MRNA $59.21 61.2 +12.9% -2.28% +25.90% +10.53% -12.60% 📈 Accumulate (uptrend, GC, +48.3% vs SMA200)
UNH $415.53 67.0 +4.3% +0.44% +10.89% +55.90% -0.49% 🔒 Hold (uptrend, GC, at ATH, +25.4% vs SMA200)
VRTX $480.18 69.2 +6.8% +4.79% +10.15% +5.83% -5.46% 🔒 Hold (basing)
CVS $103.87 71.7 ↑ +6.6% +3.90% +14.48% +47.21% -1.02% ⚠️ EXTENDED (at ATH, +30% vs SMA200)

‡TGT is not in healthcare.json (cross-list artifact); ignore.

Tier Analysis

Oversold / Collapsing (RSI < 46)

  • PFE ($23.91, RSI 27) — Pfizer: down regime, golden cross (technical), -5.3% vs SMA200, -16.9% from ATH. The lone deep-oversold name (RSI 27). Below all 3 SMAs so not clean oversold-quality, but GC + only -5% below the 200 = closest thing to a contrarian probe in the scan. Watch for a turn off the lows; don't catch it mid-flush.
  • ISRG ($400.52, RSI 38) — Intuitive Surgical: collapse, death-cross, -14.5% 3M, -33.7% from ATH, -18.2% vs SMA200. thesis: intact per engine but the trend is broken (device competition: J&J Ottava, Medtronic Hugo). BROKEN/AVOID.
  • ZTS ($77.82, RSI 40) — Zoetis: collapse, death-cross, -33% 3M, -51.9% from ATH, -34.3% vs SMA200. Worst name in the scan; no reversal. BROKEN/AVOID.
  • GILD ($124.29, RSI 42) — Gilead: pullback, golden cross, -6.5% 30D, -2.9% vs SMA200, -21% from ATH. Sitting just below the 200; watch for RSI < 40 capitulation or a reclaim.
  • VEEV ($158.08, RSI 44) — Veeva: collapse, death-cross, -49.1% from ATH, -26.7% vs SMA200. Healthcare-SaaS multiple still compressing. BROKEN/AVOID.
  • DXCM ($69.26, RSI 46) — Dexcom: pullback, -3.8% 30D, +2.9% vs SMA200 (barely), death-cross. CGM name; -5.2% below SMA20. Watch.

Neutral / Basing (RSI 56–62)

  • SYK ($316.11, RSI 56) — Stryker: downtrend, death-cross, -9.2% vs SMA200, -21.9% from ATH. Reclaiming SMA20/50 but below the 200. Ortho/medtech weak. Watch.
  • MDT ($81.29, RSI 56) — Medtronic: downtrend, death-cross, -10.5% vs SMA200, -23.6% from ATH. thesis: intact; weak-up reclaiming SMA20 only. Watch.
  • BIIB ($204.40, RSI 60) — Biogen: uptrend, golden cross, +16.2% vs SMA200, near ATH. Alzheimer's re-rate holding. Hold.
  • AMGN ($355.86, RSI 60) — Amgen: basing, golden cross, +8% vs SMA200, -9% from ATH. +5.9% 30D recovery. Clean large-cap basing setup. Hold/accumulate.
  • LLY ($1,127.69, RSI 61) — Eli Lilly: uptrend, golden cross, +25.9% 3M, +16.1% vs SMA200, -4.7% from ATH. The premier compounder. Hold.
  • ABT ($93.37, RSI 62) — Abbott: weak-up, death-cross, -16.5% vs SMA200, -32.1% from ATH but +7.7% 30D bounce. Still below the 200 — relief rally in a downtrend, not a reclaim. Watch.

Momentum / Leading (RSI 64–72)

  • TMO ($505.75, RSI 64) — Thermo Fisher: weak-up, death-cross, -3.6% vs SMA200, +13% 30D bounce, -21.5% from ATH. User-owned, thesis: intact. Lab-tools bouncing toward the 200; watch the reclaim.
  • MRK ($123.73, RSI 65) — Merck: strong-up, golden cross, +18.2% vs SMA200, near ATH (-1.1%), +7.4% 7D. Keytruda franchise re-rating; CONFIRMED-BREAKOUT but near ATH — add on a pullback.
  • JNJ ($244.84, RSI 65) — J&J: basing→strong, golden cross, +13.9% vs SMA200, near ATH (-2.7%), +6.4% 30D. Diversified-pharma thesis confirming post-Kenvue. Hold.
  • UNH ($415.53, RSI 67) — UnitedHealth: uptrend, golden cross, +55.9% 3M, +25.4% vs SMA200, at ATH (-0.5%). Strongest large-cap run in the scan; managed-care recovery. Hold — don't chase at ATH.
  • VRTX ($480.18, RSI 69) — Vertex: basing→up, +10.2% 30D, -5.5% from ATH. CF + pipeline; approaching extended.
  • CVS ($103.87, RSI 72) — CVS Health: strong-up, golden cross, +47.2% 3M, +30% vs SMA200, at ATH (-1%). EXTENDED — RSI 72 at ATH; pharmacy→insurance re-rate fully priced near-term. Don't chase; hold if owned.

Entry Zones

Stock Price Zone RSI 30D% Setup
AMGN $355.86 <$348 60.5 +5.9% Large-cap basing; GC; +8% vs SMA200; cleanest large-cap entry, add on SMA20 retest
LLY $1,127.69 <$1,118 60.6 +5.9% GLP-1 oligopoly; GC; +16% vs SMA200; near ATH; accumulate any dip
MRNA $59.21 <$57 61.2 +25.9% mRNA re-rating; +48.3% vs SMA200; GC; -2.3% 7D flag = add
MRK $123.73 <$120 64.6 +4.1% Keytruda; GC; +18% vs SMA200; near ATH — buy SMA20 pullback not the print
PFE $23.91 <$23 26.9 -7.5% Lone deep-oversold (RSI 27); GC; on SMA200; contrarian probe only on a turn

Action Matrix

Action Stocks Why
🔒 HOLD UNH, JNJ, MRK, LLY, AMGN, BIIB, VRTX Insurers + large-cap pharma anchors; trends/theses intact; don't sell strength
📈 ACCUMULATE MRNA, AMGN mRNA platform re-rating (+48% vs SMA200); AMGN clean large-cap basing setup
🔍 WATCH PFE, GILD, TMO, DXCM, SYK, MDT, ABT PFE lone oversold; rest are pullbacks/relief-bounces still below SMA200 — wait for reclaim
⚠️ EXTENDED / DON'T CHASE CVS, UNH RSI 72/67 at ATH, +30%/+25% vs SMA200 — fully priced near-term, wait for pullback
❌ BROKEN / AVOID ISRG, ZTS, VEEV Collapse regime + death-cross + below SMA200; structural de-rates not finished

What Changed

  • Large-cap pharma flipped from soft to strong — JNJ (+6.4% 30D, near ATH), MRK (+7.4% 7D, near ATH, +18% vs SMA200), AMGN (+5.9% 30D) all recovered vs last week's pullback; the anchors are now confirming.
  • UNH + CVS at ATH — UNH +55.9% 3M (RSI 67, at ATH), CVS +47.2% 3M (RSI 72, at ATH); managed-care re-rate fully extended. Don't chase.
  • MRNA breakout holds — +25.9% 30D, +48.3% vs SMA200; dual-confirmed across healthcare + biotech scans. Best momentum name; -2.3% 7D = mild flag.
  • PFE deep oversold (RSI 27) — the lone washed-out large-cap; on the SMA200 with GC intact, the closest thing to a contrarian setup.
  • Focused medtech still the loser cohort — ISRG (-14.5% 3M, collapse), SYK (downtrend), MDT (downtrend) all below SMA200; ZTS (-33% 3M) and VEEV (-49% from ATH) remain the worst names.
  • TMO/ABT relief bounces — both up 30D (+13% / +7.7%) but still below SMA200 + death-cross — relief rallies in downtrends, not reclaims.

Key Discoveries

Discovery Implication
JNJ/MRK/AMGN flipped soft→strong vs last week Large-cap pharma re-rate broadened — the risk-on bid reached the anchors, narrowing the bifurcation
Only ISRG/SYK/MDT/ZTS/VEEV still below SMA200 The structural-loser cohort shrank to focused devices + animal health + SaaS; rest of healthcare is risk-on
PFE RSI 27 alone vs leaders at ATH Single deep-oversold name in an otherwise extended sector — the lone contrarian watch, not a sector capitulation

Mistakes (Don't Repeat)

Mistake Lesson
Treating ISRG `thesis: intact` as a buy Engine tag ≠ trend; collapse + death-cross + below SMA200 = no entry despite the tag
Reading TMO/ABT 30D bounces as reclaims Up 30D but below SMA200 + death-cross = relief rally in a downtrend; wait for the actual SMA200 reclaim
Chasing CVS/UNH at ATH RSI 72/67 + 25-30% above SMA200 = the re-rate is priced; add only on pullbacks

Open Questions

  • PFE RSI 27 on the SMA200: contrarian turn setting up, or more downside before it washes out below the 200?
  • TMO/ABT relief bounces — do they reclaim SMA200 (trend turn) or fade back into the device/lab-tools downtrend?
  • UNH +55.9% 3M at ATH: does the managed-care recovery have a second leg, or is this the exhaustion top?
10 events
DateTypeEvent
Jun 26 ScanHealthcare Scan Jun 16 ScanHealthcare Scan Jun 20 ScanHealthcare Scan Jul 11 ScanHealthcare Scan Jul 7 ScanHealthcare Scan Jul 17 ScanHealthcare Scan May 29 ScanHealthcare Scan Jul 25 ScanHealthcare Scan Jul 28 ScanHealthcare Scan Jul 31 ScanHealthcare Scan

No direct external sources are attached to this read.